Chris Wallis: Hello, and thank you for joining us in today’s journal club. Today, we’re discussing a recent publication titled, Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. I’m Chris Wallis, a Fellow in Urologic Oncology at Vanderbilt. With me today is Zach Klaassen, an Assistant Professor in […]
Long-term adjuvant androgen deprivation therapy (ADT) is the current standard systemic management associated with high-dose radiotherapy (HRT) for the treatment of localized high-risk prostate cancer (PCa). The regulatory authorities have traditionally set target testosterone levels during ADT at <50 ng/dL. However, recent data suggest that additional serum TT suppression <20 ng/dL can improve clinical outcomes […]
In Wester Word, penile cancer (PC) is a rare condition (incidence less than 1/100000/year) but with severe consequences on patients’ functions and quality of life. In the past, PC surgery was based on demolitive approaches with 2cm surgical margins that guaranteed good oncological radicality and disease control but did not take into account the functional […]
In our systematic review titled “Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis,” undertaken by the European Association of Urology (EAU) Prostate Cancer Guidelines, we analyzed patient- and tumour-related prognostic factors for post-radical prostatectomy (RP) urinary incontinence (UI). 119 studies with 131.379 patients […]
Christopher Wallis: Hello and thank you for joining us for this UroToday Journal Club. Today, we are discussing the recently published EV-201 study entitled, Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma: A multicenter, single-arm, phase 2 trial. I’m Chris Wallis, a Fellow in Urological Oncology at Vanderbilt. And […]
Christopher Wallis: Hello, and thank you for joining us for this UroToday Journal Club. Today, we are discussing the recently published KEYNOTE-057 trial, pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG: an open-label, single-arm, multicenter, phase 2 study. I’m Chris Wallis, a Fellow in Urologic Oncology at Vanderbilt, and with […]
Christopher Wallis: Hello and thank you for joining us for this UroToday Journal Club. Today, we are discussing a recent publication entitled, An Adaptive Biomarker-Directed Platform Study of Durvalumab in Combination with Targeted Therapies in Advanced Urothelial Cancer. I’m Chris Wallis, a Fellow in Urologic Oncology at Vanderbilt, and with me today is Zach Klaassen, […]
Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC)1. AUC is characterized by several recurrent targetable genomic alterations2-5. This study (NCT02546661, BISCAY) combined durvalumab with relevant targeted therapies in biomarker-selected chemotherapy-refractory AUC populations including: (1) fibroblast growth factor receptor (FGFR) inhibitors in tumors with FGFR DNA alterations (FGFRm); […]
Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time.
Upper urinary tract urothelial carcinoma (UTUC) is one of the common urothelial cancers. Its molecular pathogenesis, however, is poorly understood, with no useful biomarkers available for accurate diagnosis and molecular classification.
